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1. Introduction
‘The advent of a wide spectrum of bactericidal antibiotic agents has enabled physicians to treat many cases of bacterial
endocarditis with a high likelihood of success. There remain, however, a significant number of patients with endocarditis
in whom the infection is more resistant to antimicrobial therapy, valve destruction more rapid, and a satisfactory response
to medical therapy sufficiently infrequent to warrant consideration of a new therapeutic approach’.
Circulation 1965;13:450.
Thus began the first published case report of cardiac valve replacement for infective endocar‐
ditis by Doctors Wallace, Young and Osterhout of Duke University Medical Centre. They
described a 45 year old man with Klebsiella endocarditis affecting the aortic valve in whom
severe aortic regurgitation and congestive heart failure developed which failed to respond to
medical therapy. Excision of the valve and replacement with a Starr-Edwards prosthesis was
curative. [1]
In fact, the first surgical attempts to treat infective endocarditis date back to 1937, prior to the
introduction of antibiotics, when John Strieder at the Massachusetts Memorial Hospital in
Boston ligated an infected ductus arteriosus. The patient was a 22-year old female in grave
condition. It was a matter of controversy whether ductus ligation would heal endocarditis or,
on the contrary, perhaps even exacerbate it. [2] The surgery proved difficult, and although the
patient’s immediate postoperative condition was excellent, with the typical sound of an open
ductus no longer heard, she died four days later. Postmortem examination revealed vegeta‐
tions extending from the origin of the ductus to the pulmonary valve.
© 2013 Kang and Smith; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Over the ensuing decades, developments in open-heart surgery and the evolution of cardiac
valvular prostheses have since made surgery for endocarditis part of the routine work of every
cardiac surgical unit. Nevertheless, such surgery still poses unique challenges and carries
substantial risk of morbidity and mortality. Furthermore, the indications, timing, and type of
surgery remain controversial as there are few randomized trials to guide patient management.
2. Surgical anatomy of the heart valves
It is important to appreciate that the four cardiac valves do not exist in isolation, but are closely
related to each other and also to other vital intracardiac structures. [Figure 1]
 
Figure 1. The four cardiac valves. Note the central position of the aortic valve and the fibrous skeleton of the heart
connecting mitral, tricuspid and aortic valves. Reproduced from reference [3]
The aortic, mitral and tricuspid valves are all connected at the membranous septum [4], a small
but crucial part of the heart [see Figure 2]. It separates the left ventricle from the right ventricle
(interventricular component), and also separates the left ventricle from the right atrium
(atrioventricular component). The conduction tissue (penetrating bundle) is intimately related
to the membranous septum, being sandwiched between it and the muscular septum. [3] Only
the pulmonary valve lacks fibrous continuity with the other valves, being situated on a
circumferential sleeve of cardiac muscle known as the infundibulum.
It can therefore be appreciated how a virulent, invasive intracardiac infection might become
potentially so destructive. Not only can the primary valve be affected, but infection can spread
into adjacent valves, fistulas can develop into the cardiac chambers or pericardial space, the
fibrous skeleton of the heart can be eroded and the conduction system can be destroyed.
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Figure 2. Membranous septum. The tricuspid annulus has been detached from the membranous septum in this pro‐
section. Ao aorta, BR basal ring, L left coronary sinus, ms membranous septum, NC non coronary sinus, RCA right coro‐
nary artery, STJ sinotubular junction. Reproduced with permission from reference [4]
3. Indications for surgery in native valve endocarditis
The proportion of patients with endocarditis treated surgically varies widely amongst
individual units, reflecting the fact that most indications for surgery are not absolute. Large
multicentre studies report overall rates of surgery of approximately 40-50%. [5-7]
In recent years, international guidelines for valvular heart surgery and, more specifically,
infective endocarditis have been published by a number of collaborative task forces. These task
forces have examined the relevant scientific literature available and made evidence based
recommendations accordingly for best practice guidelines.
The American College of Cardiology and American Heart Association (ACC/AHA) published
their updated guidelines for valvular heart disease in 2008. [8] A section of these guidelines is
devoted to infective endocarditis. In native valve endocarditis (NVE), the strongest recom‐
mendations for surgery apply to those patients with signs of heart failure, adverse haemody‐
namic effects from regurgitant valve lesions, antibiotic resistant organisms, or locally invasive
cardiac infection with destruction of perivalvular structures. The recommendation for surgery
is present, but weaker, in patients with recurrent embolic events and/or very large vegetations.
Table 1 summarises these recommendations.
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Class I
1. Surgery of the native valve is indicated in patients with acute infective endocarditis who present with valve stenosis
or regurgitation resulting in heart failure. (Level of Evidence: B)
2. Surgery of the native valve is indicated in patients with acute infective endocarditis who present with AR or MR with
hemodynamic evidence of elevated LV end-diastolic or left atrial pressures (e.g., premature closure of MV with AR,
rapid decelerating MR signal by continuous wave Doppler (v-wave cutoff sign), or moderate or severe pulmonary
hypertension). (Level of Evidence: B)
3. Surgery of the native valve is indicated in patients with infective endocarditis caused by fungal or other highly
resistant organisms. (Level of Evidence: B)
4. Surgery of the native valve is indicated in patients with infective endocarditis complicated by heart block, annular or
aortic abscess, or destructive penetrating lesions (e.g., sinus of Valsalva to right atrium, right ventricle, or left atrium
fistula; mitral leaflet perforation with aortic valve endocarditis; or infection in annulus fibrosa). (Level of Evidence: B)
Class IIa
1. Surgery of the native valve is reasonable in patients with infective endocarditis who present with recurrent emboli
and persistent vegetations despite appropriate antibiotic therapy. (Level of Evidence: C)
Class IIb
1. Surgery of the native valve may be considered in patients with infective endocarditis who present with mobile
vegetations in excess of 10 mm with or without emboli. (Level of Evidence: C)
Class I: Conditions for which there is evidence for and/or general agreement that the procedure or treatment is bene‐
ficial, useful, and effective.
Class II: Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/effica‐
cy of a procedure or treatment.
Class IIa: Weight of evidence/opinion is in favor of usefulness/efficacy.
Class IIb: Usefulness/efficacy is less well established by evidence/opinion.
Class III: Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful/
effective and in some cases may be harmful. In addition, the weight of evidence in support of the recommendation is
listed as follows:
• Level of Evidence A: Data derived from multiple randomized clinical trials.
• Level of Evidence B: Data derived from a single randomized trial or nonrandomized studies.
• Level of Evidence C: Only consensus opinion of experts, case studies, or standard-of-care.
Table 1. AHA/ACC guidelines for NVE
The ACC/AHA guidelines also state that “prosthetic valve endocarditis and native valve
endocarditis caused by Staphylococcus aureus are almost always surgical diseases”, suggest‐
ing that this organism causes particularly virulent intracardiac infection which tends to be
more destructive and consequently more difficult to eradicate with antibiotic treatment alone.
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In 2009, the European Society of Cardiology (ESC) published their own set of guidelines on
the prevention, diagnosis and treatment of endocarditis. [9] The recommendations for surgery
follow similar themes to the ACC/AHA guidelines, with heart failure, uncontrolled infection
and prevention of embolism representing the three broad categories of indications for surgery
(see Table 2).
Indications for surgery in NVE Timing Class Level
A – HEART FAILURE
Aortic or mitral IE with severe acute regurgitation or valve obstruction
causing refractory pulmonary oedema or cardiogenic shock Emergency I B
Aortic or mitral IE with fistula into a cardiac chamber or pericardium
causing refractory pulmonary oedema or cardiogenic shock Emergency I B
Aortic or mitral IE with severe acute regurgitation or valve obstruction and
persisting heart failure or echocardiographic signs of poor haemodynamic
tolerance (early mitral closure or pulmonary hypertension)
Urgent I B
Aortic or mitral IE with severe regurgitation and no HF Elective IIa B
B-UNCONTROLLED INFECTION
Locally uncontrolled infection (abscess, false aneurysm, fistula, enlarging
vegetation) Urgent I B
Persisting fever and positive blood cultures >7-10 days Urgent I B
Infection caused by fungi or multiresistant organisms Urgent/elective I B
C- PREVENTION OF EMBOLISM
Aortic or mitral IE with large vegetations (>10mm) following one or more
embolic episodes despite appropriate antibiotic therapy Urgent I B
Aortic or mitral IE with large vegetations (>10mm) and other predictors of
complicated course (heart failure, persistent infection, abscess) Urgent I C
Isolated very large vegetations (>15mm) urgent IIb C
Table 2. ESC guidelines for NVE
More recently published data from a large non-randomised prospective multicentre trial of
1552 patients with NVE found an overall survival benefit for surgery compared with medical
therapy (12.1% mortality versus 20.7%). [10] In subgroup analysis using propensity scores,
surgery was found to confer a survival benefit compared with medical therapy among patients
with a higher propensity for surgery and those with paravalvular complications, systemic
embolization, Staphylococcus aureus NVE and stroke.
Surprisingly, neither valve perforation nor congestive heart failure predicted a survival benefit
for early surgery in this study, which goes against prior assumptions and experiences. [11] It
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may be that the severity of heart failure, which was not specified in the study, does in fact
influence outcome as reported by others. [12]
4. Timing of surgery
Deciding upon the optimal timing of surgery is one of the great difficulties in managing
patients with endocarditis. As Farzaneh-Far and Bolger state in a recent editorial, “the decision
to commit to a surgical procedure that might possibly be avoided is quite difficult for the
patient, the surgeon, and the referring physician…Because patients with endocarditis span
such a wide range of comorbidities, complications, and manifestations, generalization from a
disparate population is unsatisfying.” [11]
The difficulty is compounded by the fact that available evidence to recommend timing of
surgery in endocarditis is largely limited to observational data and expert opinion. Studies
employing propensity modelling to try and overcome selection bias have been reported. [10]
More recently, the first randomized controlled trial in endocarditis was published to help
define the optimal timing of surgery, [13] as discussed below.
The timing of surgery can be considered in the following clinical situations:
a. Congestive heart failure.
The ESC guidelines advise emergency surgery for patients with persistent pulmonary oedema
or cardiogenic shock, and urgent surgery when heart failure is less severe. [9] In patients with
well tolerated severe valvular insufficiency (i.e. mild or no heart failure) and no other reasons
for surgery, the guidelines recommend ‘medical management with antibiotics under strict
clinical and echocardiographic observation’ with surgery to be considered ‘after healing of
infective endocarditis, depending on tolerance of the valve lesion’.
b. Systemic embolism
Systemic embolism occurs in up to 50% of patients with infective endocarditis, most frequently
to the central nervous system and specifically to the territory of the middle cerebral artery [14].
A number of studies have demonstrated that embolic risk falls substantially after the first 2-3
weeks of treatment. [15, 16] The presence of large (>15mm on echocardiogram) vegetations
has been considered a relative indication for early surgery, particularly in Staphylococcal
endocarditis affecting the mitral valve. [15]
Recently the benefit of early surgery in this context was investigated in the first randomized
trial in endocarditis [13]. In this study, 76 patients with left-sided native valve infective
endocarditis, vegetations greater than 10 mm, and severe valve dysfunction were randomly
assigned to surgery within 48 hours or antibiotic therapy. The primary end point was a
composite of embolic events or death within 6 weeks after randomization. Secondary end
points were embolic events, recurrent endocarditis, repeat hospitalization due to the devel‐
opment of congestive heart failure, or death from any cause at 6 months.
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The major finding in this study was that early surgery significantly reduced the composite end
point of embolic events and death from any cause, by effectively decreasing the risk of systemic
embolism. The authors suggest that early surgery is therefore a valuable therapeutic option to
prevent embolism.
c. Embolic stroke
Timing of surgery after embolic stroke poses an especially difficult dilemma. Early surgery
carries a risk of haemorrhagic transformation of cerebral infarction, whilst delaying surgery
may lead to further embolic events and/or worsening of cardiac function. In a recent review
of 100 published studies, Rossi et al concluded that “evidence is conflicting because of lack of
controlled studies” [17]. They state that “the optimal timing for the valve replacement depends
on the type of neurological complication and the urgency of the operation.”
The ESC guidelines suggest that if cerebral haemorrhage has been excluded and neurological
damage is not severe, surgery should not be delayed. [9] The risk of further neurological
complication is low and full neurological recovery may be possible.
Conversely, in cases with intracranial haemorrhage, neurological prognosis is worse and ESC
guidelines suggest that surgery should be postponed for at least one month. If the possibility
of mycotic aneurysm is suspected, the patient should be evaluated with cerebral angiography
as such aneurysms are a contraindication for anticoagulation as well. [18]
In all such cases, consultation with neurology and neurosurgical teams is advisable.
d. Paravalvular extension
As emphasized in the preceding section on cardiac anatomy, paravalvular abscess formation
has a high probability of impairing cardiac conduction and leading to multi-valve involve‐
ment. Extension of infection is very common in prosthetic valve endocarditis and affects
10-40% of native aortic valve infection. The diagnosis is best made by transoesophageal
echocardiography and should be suspected whenever there is any degree of atrioventricular
block present. Urgent surgery is indicated once the diagnosis is made.
5. Decision making
It is evident from the above that decision making with regards to both the indications and
timing of surgery is still problematic. Because infective endocarditis can have such variable
clinical manifestations, treatment must of necessity be tailored to individual patient circum‐
stances, the nature of the organism, its effect on the heart and other organs, duration of
antibiotic therapy already received, progression of disease over time, and numerous other
considerations.
Currently available guidelines aid decision making but are founded largely on observational
data. Despite the protean difficulties in designing randomized trials in endocarditis, the
pioneering study cited above [13] illustrates that the task is not impossible. Given that
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endocarditis remains a frequent, important and potentially lethal condition, the challenge of
acquiring more definitive evidence should be accepted.
6. Operative management
Surgery for endocarditis can be amongst the most challenging operations faced by the cardiac
surgeon. Debriding infected cardiac tissue and restoring anatomical and functional integrity
can be a test of considerable surgical skill. Furthermore, patients present for operation in
varying degrees of septicaemia, cardiac failure, multiorgan failure, shock, coagulopathy,
hypoproteinemia and anasarca, to which the further insults of surgical trauma and cardio‐
pulmonary bypass are added.
6.1. Surgical principles
The primary objectives of surgery are (1) eradication of all infected, necrotic and non-viable
tissue and (2) reconstruction of cardiac morphology. [9] How this is achieved surgically is very
dependent upon the local extent of intracardiac infection. Surgery may thus entail repair or
replacement of one or more valves, complete aortic root replacement, debridement and
patching of abscesses, closure of fistulas, or reconstruction of part of the fibrous skeleton of
the heart. Cardiac transplantation has even been reported in an extreme case of relapsing ‘burnt
out’ endocarditis with multiple previous unsuccessful surgeries over many years. [19]
6.2. Valve repair
Valve repair, rather than replacement, is theoretically an attractive option in endocarditis when
infection is limited in its local extent. Not only does repair avoid the inherent problems of
prosthetic valves (e.g. anticoagulation, thromboembolism, paravalvular leak, structural valve
deterioration) but it reduces the risk of recurrent endocarditis when compared with valve
replacement. [20].
Techniques may involve simple vegetectomy alone, patching of leaflet perforations with
pericardium, or more sophisticated methods of leaflet and/or chordal reconstruction. The
method used must be tailored to the individual pathology present (see Figure 4). Eradicating
the infection and achieving a durably competent valve is the goal of repair.
Valve repair techniques are now well established for the treatment of degenerative mitral valve
disease, but are not always feasible in the setting of endocarditis. In a metanalysis of 24 studies
comparing repair versus replacement in 1194 patients, 39% of patients underwent repair whilst
the remainder required replacement. Repair was associated with superior early and late
outcomes, with reduced need for repeat mitral surgery, fewer cerebrovascular events and
fewer episodes of recurrent endocarditis. Operative mortality was less than 10% and 5-year
survival greater than 80%. [20]
It is important to appreciate, however, that all 24 studies in the metanalysis were retrospective
observational series and thus subject to both selection bias and publication bias. As was noted
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in the meta-analysis, “the validity of comparing mitral valve repair with mitral valve replace‐
ment may be questioned. Mitral valve replacement is often reserved for the sickest patients in
whom mitral valve repair cannot be performed. Therefore, it would not be surprising that
postoperative results would be worse for these patients.” [20]
Valve repair is a much less well established but nonetheless emerging technique in aortic valve
disease. Mayer et al reported a series of 100 patients undergoing surgery for aortic valve
endocarditis; 33 treated by repair and 67 by replacement. [22] Five year survival was signifi‐
cantly higher in the repair group, although again this was a retrospective series with inherent
selection bias. In addition, it is worth noting that the subgroup of patients with repaired
bicuspid valves had a higher rate of late aortic regurgitation.
6.3. Valve replacement
Valve replacement, as first performed by Dr W Glenn Young Jr at the Duke University Medical
Center [1] nearly 50 years ago, remains the standard of care in the majority of cases of endo‐
carditis treated surgically.
The optimal choice of valve substitute in the setting of infective endocarditis has long been
debated. Once again, only observational data rather than randomized clinical trials are
available to guide clinical practice.
Some investigators have reported that valve replacement using a homograft results in a lower
rate of recurrent endocarditis. [23, 24] Most surgeons now believe that the choice of valve
substitute is less important in determining recurrence than the completeness of debridement
at the time of operation. Homografts have the disadvantage of more difficult reoperation at
Figure 3. Mitral valve repair. Reproduced with permission from reference [21]. The vegetation involving the postero‐
medial commissure has been resected, and the posterior leaflet mobilised and advanced into the commissure. The
valve must be competent following repair, otherwise replacement will be necessary.
Surgical Management of Infective Endocarditis
http://dx.doi.org/10.5772/56761
93
the time of their inevitable structural deterioration. For NVE confined to the valve leaflets,
operative results are similar for mechanical and biological prostheses. [25, 8]
6.4. Aortic root replacement
Sometimes, simple valve replacement may not be sufficient when dealing with paravalvular
infection, resulting in reinfection of the prosthesis, valve dehiscence, or both. [18] This is often
the case in prosthetic valve endocarditis (see below) Aortic root replacement, as opposed to
simple aortic valve replacement, may therefore be necessary in these circumstances. Aortic
root replacement involves excision of the aortic valve cusps, the sinuses of Valsalva, and a
variable amount of the distal ascending aorta. The coronary arteries have to be reimplanted
into the replaced root.
In these situations, root replacement with a homograft can be advantageous. The homograft
aortic root is soft, pliable, and can be tailored to patch abscess cavities and rebuild tissue
defects, especially if the anterior mitral leaflet of the homograft has been left attached. [24]
 
Figure 4. Aortic root replacement using a homograft. Reproduced with permission from reference [24]. The attach‐
ed homograft mitral leaflet has been used to reconstruct the debrided abscess cavity in the aortic-mitral curtain
Homografts, however, are limited in their availability. Stentless xenograft valves exhibit
similar properties to homografts and have been used in this setting as an alternative. [26]
Standard mechanical valved conduits have also been used with very satisfactory results. [27,
28] The pulmonary autograft (Ross procedure) is another option although this adds greater
complexity to an already difficult procedure in a sick patient. As previously emphasised, the
completeness of debridement is probably more important than the type of cardiac replacement
tissue used.
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6.5. Reconstruction of the fibrous skeleton
In very advanced cases of endocarditis, there may be extensive tissue destruction around the
aorto-ventricular junction, mitral annulus and aorto-mitral curtain. In addition to replacing
both aortic and mitral valves, the fibrous skeleton of the heart itself may need to be recon‐
structed. (see Figure 5). Such patients may in fact prove to be beyond surgical repair and
deemed inoperable. Complex techniques of surgical reconstruction have been reported by
some groups, notably David et al. [29]
Figure 5. Complex reconstruction of the mitral annulus and aortic-mitral curtain using a pericardial patch. Re‐
produced with permission from reference [29]. Both aortic and mitral valves have been excised, as well as the inter‐
vening area of fibrous continuity (aortic-mitral curtain). The patch acts as a new fibrous skeleton upon which to
anchor sutures to secure the aortic and mitral valve prostheses.
7. Prosthetic valve endocarditis
Prosthetic valve endocarditis (PVE) is one of the most feared conditions in cardiac surgery. It
accounts for approximately 20% of cases of IE. [7] Mechanical and bioprosthetic valves are
equally affected at a frequency in the order of 1% per patient year.
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PVE is traditionally classified into early (within 60 days of original valve replacement surgery)
and late (greater than 60 days), although a cut-off of 12 months has been suggested by some.
[30] The implication is that in early PVE the infection has been acquired at the time of original
surgery, whereas in late PVE it complicates a subsequent unrelated bacteraemic episode.
The rate of paravalvular infection is much higher in PVE than NVE, owing to the presence of
the prosthetic sewing ring. With mechanical valve prostheses, paravalvular abscess is present
in virtually all cases. With bioprosthetic valves, infection is sometimes confined to the valve
leaflets, but more often the sewing ring is involved as well.
Paravalvular infection in the aortic position can rapidly lead to aortic root abscess, fistulas into
cardiac chambers, disruption of the aortic-mitral curtain, and even complete aorto-ventricular
dehiscence. [24, 26] Surgery to remedy these problems is made substantially more complex in
view of the fact that these are reoperations. This degree of surgical complexity is reflected in
the operative mortality, which is typically double that for NVE surgery [7, 31, 32] (see ‘Results
of Surgery’ section below).
The decision as to whether to operate or not for PVE is difficult. Operative risk is much greater
for PVE than NVE, but the mortality with medical treatment alone is similarly higher, resulting
in a management dilemma. Essentially, patients with early PVE, Staphylococcal PVE and
complicated PVE (abscess, heart failure, prosthetic valve dysfunction) are more likely to
require surgery whereas late PVE, non-Staphylococcal PVE and uncomplicated PVE can be
managed medically with close follow-up. [9]
Tables 3 and 4 summarise the AHA/ACC and ESC guidelines respectively for PVE.
Class I
1. Consultation with a cardiac surgeon is indicated for patients with infective endocarditis of a prosthetic valve. (Level of Evidence: C)
2. Surgery is indicated for patients with infective endocarditis of a prosthetic valve who present with heart failure. (Level of Evidence: B)
3. Surgery is indicated for patients with infective endocarditis of a prosthetic valve who present with dehiscence evidenced by cine
fluoroscopy or echocardiography. (Level of Evidence: B)
4. Surgery is indicated for patients with infective endocarditis of a prosthetic valve who present with evidence of increasing obstruction or
worsening regurgitation. (Level of Evidence: C)
5. Surgery is indicated for patients with infective endocarditis of a prosthetic valve who present with complications (e.g., abscess
formation). (Level of Evidence: C)
Class IIa
1. Surgery is reasonable for patients with infective endocarditis of a prosthetic valve who present with evidence of persistent bacteremia
or recurrent emboli despite appropriate antibiotic treatment. (Level of Evidence: C)
2. Surgery is reasonable for patients with infective endocarditis of a prosthetic valve who present with relapsing infection. (Level of
Evidence: C)
Class III
1. Routine surgery is not indicated for patients with uncomplicated infective endocarditis of a prosthetic valve caused by first infection
with a sensitive organism. (Level of Evidence: C)
Table 3. AHA/ACC guidelines for PVE
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Indications for surgery in PVE Timing Class Level
A – HEART FAILURE
PVE with severe prosthetic dysfunction (dehiscence or obstruction) causing
refractory pulmonary oedema or cardiogenic shock Emergency I B
PVE with fistula into a cardiac chamber or pericardium causing refractory
pulmonary oedema or cardiogenic shock Emergency I B
PVE with severe prosthetic dysfunction and persisting heart failure Urgent I B
Severe prosthetic dehiscence without HF Elective I B
B-UNCONTROLLED INFECTION
Locally uncontrolled infection (abscess, false aneurysm, fistula, enlarging
vegetation) Urgent I B
PVE caused by fungi or multiresistant organisms Urgent/elective I B
PVE with persisting fever and positive blood cultures >7-10 days Urgent I B
PVE caused by staphylococci or gram negative bacteria (most cases of early
PVE) Urgent/elective IIa C
C- PREVENTION OF EMBOLISM
PVE with recurrent emboli despite appropriate antibiotic treatment Urgent I B
PVE with large vegetations (>10mm) and other predictors of complicated
course (heart failure, persistent infection, abscess) Urgent I C
PVE with isolated very large vegetations (>15mm) urgent IIb C
Table 4. ESC guidelines for PVE
8. Right heart endocarditis
Endocarditis can affect the tricuspid valve, pulmonary valve, right ventricle or right atrium
and accounts for up to 10% of cases. Predisposing risk factors for right sided endocarditis
include intravenous drug abuse and the presence of foreign bodies such as pacemaker leads,
haemodialysis catheters, other central venous catheters and valvular prostheses. Congenital
anomalies such as ventricular septal defects and bicuspid pulmonary valves also predispose
to right heart endocarditis.
Right heart endocarditis is characterised by large, friable vegetations which embolise readily
to the pulmonary circulation. The resultant lung abscesses occasionally rupture causing
empyema and bronchopleural fistula (see Figure 6). Staphylococcus aureus is the dominant
organism, but fungal and Gram negative infections also occur.
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Figure 6. Computed tomography scan demonstrating florid embolic lung abscesses with cavitation, bronchopleural
fistula and pyopneumothorax in a patient with pulmonary valve endocarditis due to Staphylococcus aureus.
Clinical manifestations are typically those of fever and respiratory distress, but severe
haemodynamic compromise and shock may occasionally occur due to sepsis, rather than direct
effects on valvular heart function. [33]
Decision making in right heart endocarditis is often problematic, because the indications for
surgery are less well defined than for left-sided endocarditis. Many cases can be managed
successfully without the need for surgical intervention; however large vegetations (>2cm),
fungal infection, heart failure and intractable sepsis should prompt consideration for operative
intervention. [33-35, 9] Table 5 summarises the indications for surgery in RSE according to the
ESC guidelines.
Recommendations: right-sided endocarditis Class Level
Surgical treatment should be considered in the following scenarios:
• Microorganisms difficult to eradicate (e.g. persistent fungi) or bacteraemia for >7 days (e.g. S.
aureus, P. aeruginosa) despite adequate antiomicrobila therapy or
• Persistent tricuspid valve vegetations >20mm after recurrent pulmonary emboli with or without
concomitant right heart failure or
• Right heart failure secondary to severe tricuspid regurgitation with poor response to diuretic
therapy
IIa C
Table 5. ESC guidelines for right-sided endocarditis
In cases of infected transvenous pacemaker leads, percutaneous removal is generally recom‐
mended, despite the risk of dislodging vegetations and causing pulmonary embolism. Surgery
is reserved for cases where percutaneous removal is incomplete or impossible, where vegeta‐
tions are very large (>25mm) or where there is associated severe destructive tricuspid valve
disease. [9]
Recent Advances in Infective Endocarditis98
The principles of surgery for right heart endocarditis are similar to left-sided disease, namely
thorough debridement of infected and necrotic tissue, removal of all infected foreign material
and valvular reconstruction or replacement as required. Many cases of tricuspid valve
endocarditis can be treated successfully with vegetectomy and valve repair, but replacement
may be necessary with more extensive infection.
Because of the risk of recurrent infection in intravenous drug abusers, valve replacement
should be avoided whenever possible in this patient group. If replacement is necessary, future
compliance with anticoagulation becomes an important consideration when deciding upon
mechanical versus bioprosthetic valves. An alternative is valvectomy without replacement,
but the resultant free valvular regurgitation may not be tolerated acutely in some patients and
late results are less satisfactory.
9. Results of surgery
The contemporary results of surgery for infective endocarditis indicate that this is still a
difficult surgical condition with substantial risk of postoperative morbidity and mortality.
The Cleveland Clinic reported a series of 428 patients undergoing surgery between 2003 and
2007 with an overall hospital mortality of 10%. [32] Prosthetic valve endocarditis had a
significantly higher mortality compared with NVE (13% versus 5.6%). Infection with Staphy‐
lococcus aureus also predicted a higher early and late mortality in this series.
Toronto General Hospital reported a series of 383 patients undergoing surgery for infective
endocarditis over a 26-year period between 1978 and 2004. [31] Hospital mortality was 12%.
Age, shock, prosthetic valve endocarditis, left ventricular ejection fraction less than 40%, and
recurrent endocarditis were independent predictors of death from all causes in this series.
A multicentre prospective study of 1516 patients with NVE was published by Cabell et al in
2005 [5]. Six hundred and ten patients underwent surgery and the remaining 906 were treated
medically. Hospital mortality was similar in the two groups (13.6% versus 16.4%). However,
propensity analysis identified a significant survival benefit for surgery (11.2% mortality versus
38%) in the subgroup with the most number of predictors for surgery, namely male gender,
congestive heart failure, aortic valve involvement, and intracardiac abscess. The authors
conclude that the benefits of surgery are most realised in a targeted population.
The same investigators also examined the results of treatment for PVE. [7] Of 355 patients with
PVE, 148 underwent surgery and 207 received medical treatment alone. Unadjusted hospital
mortality was similar in the two groups (25% versus 23.4%). Brain embolism and Staphylo‐
coccus aureus were independent predictors of mortality.
In the 2010 prospective multicentre study of NVE by Lalani et al [10] quoted earlier, mortality
in 720 patients treated surgically was 12.1%. This compared favourably with the 20.7%
mortality for medical treatment.
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In summary, surgery for infective endocarditis is associated with an overall hospital mortality
of approximately 10-20%. The risk is roughly doubled in PVE compared with NVE.
10. Summary
Surgery for infective endocarditis has evolved enormously since its origins 75 years ago.
Guidelines now exist to recommend the indications, timing, and type of surgery, yet much of
the evidence is founded on observational data rather than randomized clinical trials. More
than perhaps any other surgical issue, decisions rely as much on the experience and judgement
of the individual surgeon as the largely observational evidence accumulated in the literature.
The principles of surgery remain essentially unchanged, namely the debridement of all
infected and non-viable tissue. Valve replacement is the standard of care in the majority of
cases, but valve sparing techniques of repair have also gradually evolved. More extensive
cardiac reconstruction with root replacement and other methods are sometimes necessary in
locally advanced infection. Operative mortality and morbidity is still significant, particularly
for prosthetic valve endocarditis.
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